Brief: Hepion Pharmaceuticals Announces Publication Of Phase 2A ‘Ambition’ Clinical Trial Results
26/10/2022 13:18
Oct 26 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS ANNOUNCES PUBLICATION OF PHASE 2A
‘AMBITION’ CLINICAL TRIAL RESULTS
* HEPION PHARMACEUTICALS INC - STUDY MET SAFETY,
TOLERABILITY, AND
PHARMACOKINETICS PRIMARY ENDPOINTS
* HEPION PHARMACEUTICALS INC - REDUCTIONS IN ALT, PROC3, AND
C6M
SUGGEST DIRECT ANTIFIBROTIC EFFECTS WITH LONGER TREATMENT
DURATION
* HEPION -ENROLLMENT INITIATED IN PHASE 2B 'ASCEND-NASH'
TRIAL
EVALUATING SAFETY, EFFICACY OF RENCOFILSTAT IN 336 BIOPSY
CONFIRMED F2 / F3 NASH SUBJECTS
Source text for Eikon: ID:nGNX1XdtsR
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement